Resistance to targeted therapy in leukaemia

Lancet

Volumn 359, Issue 9305, 2002, Pages 458-459

  Griffin, James D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; NONHUMAN; NOTE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RELAPSE; SIGNAL TRANSDUCTION;

EID: 0037045574     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07671-7     Document Type: Note

References (7)

1. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
2. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
3. All trans retinoic acid in acute promyelocytic leukemia
4. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
5. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
6. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy
7. Mechanisms of resistance to imatinib (STI571) in preclinical models and in leukemia patients